MID-35 is a laboratory-made protein fragment built to block the body's own brake on muscle growth. One injection kept mouse muscle larger for months. Every finding comes from mice, from the laboratory that invented the compound. No person has ever received it, no approved source exists, and no human dose is known. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Appendicular lean mass index (DEXA) | Men ≥ 7.5 kg/m²; women ≥ 6.0 kg/m² | The primary success measure — regional muscle mass |
| Creatine kinase (CK) | 40–200 U/L | Detects muscle fiber damage from injection trauma |
| High-sensitivity C-reactive protein (hs-CRP) | < 0.5 mg/L | Flags local or systemic inflammatory response to repeated injection |
| Serum myostatin (GDF-8) | No established target; track change from the individual's own baseline | The only direct read on whether the signal is actually being blocked |
| Estimated glomerular filtration rate (eGFR) | > 90 mL/min/1.73 m² | Peptide clearance depends on kidney function |
| Alanine aminotransferase (ALT) | Men 10–30 U/L; women 8–25 U/L | Baseline liver status before exposure to an unstudied compound |
| Complete blood count with platelets (CBC) | Platelets 175–250 ×10⁹/L; hemoglobin 13.5–15.0 g/dL (men), 12.5–14.5 (women) | Bleeding margin for intramuscular injection, and a check on the class bleeding signal |
| Glycated hemoglobin (HbA1c) | 4.8–5.3% | Myostatin-pathway blockade shifts glucose handling in human trials |
Cadence: Baseline set before any exposure; safety subset repeated at 2 weeks and 4 weeks after first exposure, then every 3 months while use continues; body composition reassessed at 3 and 6 months; full panel annually thereafter.